Related Experiment Video
Updated: Aug 14, 2025
08:37
Echocardiographic Assessment Using Subxiphoid-Only Examination for Hypotensive Patients
Published on: April 18, 2025
387
Multimodal strategy to counteract vasodilation in septic shock
Marc Leone1, Sharon Einav2, Elio Antonucci3
1Department of Anesthesiology and Intensive Care Unit, North Hospital, Aix Marseille University, Assistance Publique Hôpitaux Universitaires de Marseille, Marseille, France.
Anaesthesia, Critical Care & Pain Medicine
|January 9, 2023
Summary
Early use of multiple vasopressors in septic shock improves organ perfusion. Combining therapies like norepinephrine with vasopressin or methylene blue may reduce catecholamine doses and enhance outcomes.
Area of Science:
- Critical Care Medicine
- Pharmacology
- Sepsis Pathophysiology
Background:
- Septic shock involves widespread vasodilation, leading to inadequate organ perfusion.
- High-dose catecholamines, while effective, carry significant side effects.
- Early intervention is crucial to restore hemodynamics and prevent organ damage.
Purpose of the Study:
- To review the pathophysiology of vasodilation in septic shock.
- To explore multimodal vasopressor strategies for early management.
- To discuss optimizing vasopressor selection and timing.
Main Methods:
- Literature review summarizing vasodilation pathophysiology and vasopressor mechanisms.
- Analysis of combining different vasopressor agents (adrenergic, vasopressinergic, renin-angiotensin systems).
- Discussion on enhancing endothelial reactivity with agents like methylene blue.
Main Results:
- Fluid resuscitation alone is often insufficient to counteract vasoplegia.
- Norepinephrine is a common first-line agent, but combination therapy can spare its use.
- Concomitant use of various systems and methylene blue shows potential for improved outcomes.
Conclusions:
- Early multimodal vasopressor strategies are essential in septic shock management.
- Combining different vasopressors and optimizing endothelial function may improve perfusion and reduce catecholamine toxicity.
- A framework for future studies on vasopressor selection and timing is proposed.
Related Concept Videos
01:24Blood Pressure Imbalances and Circulatory Shock
928
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
928
01:23Antihypertensive Drugs: Vasodilators
606
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
606
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
481
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
01:22Heart Failure Drugs: β-Blockers
412
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
412
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
62
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
62
01:30Heart Failure V: Medical Management
19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19